Payment overview · 2025
General Payments
$703.25
21 reported records · 10 companies
Healthcare provider profile · identity verified
Jorge A Rivero, MD
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · LAGUNA HILLS, CA · NPI 1013097260
Verified facts
What the public records show
CMS Open Payments records show Jorge A Rivero, MD received $703.25 in general payments during 2025 across 21 reported records.
Amgen Inc. accounted for 48.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $339.37 | 48.3% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $173.72 | 24.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.61 | 7.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.71 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.83 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.62 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.25 | 2.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.12 | 2.7% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $17.62 | 2.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.40 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $703.25 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $202.74 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $136.63 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $116.82 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $65.80 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $56.90 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $28.23 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| IVAS Normalized: ivas |
Device | Stryker Corporation | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 358 | 103 |
| Lisinopril | Lisinopril | 258 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 61 |
| Metformin Hcl | Metformin Hcl | 206 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 61 |
| Losartan Potassium | Losartan Potassium | 190 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 58 |
| Gabapentin | Gabapentin | 154 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 39 |
| Glipizide | Glipizide | 110 | 30 |
| Simvastatin | Simvastatin | 108 | 31 |
| Furosemide | Furosemide | 106 | 36 |
| Memantine Hcl | Memantine Hcl | 105 | 19 |
| Sertraline Hcl | Sertraline Hcl | 99 | 31 |
| Alendronate Sodium | Alendronate Sodium | 92 | 30 |
| Omeprazole | Omeprazole | 90 | 26 |
| Trazodone Hcl | Trazodone Hcl | 82 | 27 |
| Lorazepam | Lorazepam | 80 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 24 |
| Atenolol | Atenolol | 71 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 21 |
| Mirtazapine | Mirtazapine | 63 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 61 | 22 |
| Meloxicam | Meloxicam | 59 | 14 |
| Alprazolam | Alprazolam | 57 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 19 |
| Spironolactone | Spironolactone | 55 | 13 |
| Synthroid | Levothyroxine Sodium | 52 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 15 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Celecoxib | Celecoxib | 48 | 11 |
| Famotidine | Famotidine | 48 | 14 |
| Potassium Chloride | Potassium Chloride | 48 | 13 |
| Azithromycin | Azithromycin | 47 | 35 |
| Carvedilol | Carvedilol | 44 | 14 |
| Tramadol Hcl | Tramadol Hcl | 44 | 16 |
| Temazepam | Temazepam | 41 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 17 |
| Finasteride | Finasteride | 39 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 31 |
| Ozempic | Semaglutide | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 11 |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 13 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 12 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 11 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 13 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 13 |
| Hydrocortisone | Hydrocortisone | 22 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 15 |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $703.25 · 21 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, EVENITY, IVAS, JYNARQUE, KISUNLA, OTEZLA, PREVNAR 20, PROLIA, REPATHA, REXULTI, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error